The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service routinely offer GlaxoSmithKline (GSK)’s Zejula (niraparib) for women with ovarian, peritoneal or fallopian tube cancers.

NICE’s endorsement covers women whose cancer has relapsed and who have previously undergone two prior lines of platinum-based chemotherapy.

Previously, the drug was offered by NHS through a limited, managed access program. More than 400 women with these reproductive cancers will now have access to the treatment, NICE said.

Zejula inhibits an enzyme, poly-adenosine diphosphate-ribose polymerase (PARP), to stop cancer cells from repairing damaged DNA and spreading.